Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers

Published:2020-04 Issue:3 Volume:9 Page:395-410
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Badman Michael K.¹,Chen Jin²,Desai Sachin¹,Vaidya Soniya¹,Neelakantham Srikanth³,Zhang Jie¹,Gan Lu¹⁴,Danis Kate¹⁵,Laffitte Bryan⁶⁷,Klickstein Lloyd B.¹

Affiliation:

1. Novartis Institutes for BioMedical Research Cambridge Massachusetts USA

2. Novartis Institutes for BioMedical Research East Hanover New Jersey USA

3. Novartis Healthcare Pvt. Ltd. Hyderabad India

4. Current affiliation: X4 Pharmaceutical Inc. Cambridge Massachusetts USA

5. Current affiliation: Takeda Pharmaceutical Company Ltd. Lexington Massachusetts USA

6. Genonics Institute of the Novartis Research Foundation San Diego California USA

7. Current affiliation: Inception Sciences Inc. San Diego California USA

Funder

Novartis Institutes for BioMedical Research

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.762

Reference33 articles.

1. Identification of a Nuclear Receptor for Bile Acids

2. Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

3. Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR

4. Natural Structural Variants of the Nuclear Receptor Farnesoid X Receptor Affect Transcriptional Activation

5. FXR regulates organic solute transporters α and β in the adrenal gland, kidney, and intestine

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases;Medical Review;2024-06-04

2. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis;Expert Opinion on Investigational Drugs;2024-05-07

3. Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders;Saudi Journal of Gastroenterology;2024-05-06

4. Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease;Bioorganic Chemistry;2024-02

5. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies;Pharmacological Reviews;2024-01-30